

GLAXOSMITHKLINE PLC  
Form 6-K  
July 11, 2008

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending July 11, 2008

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or  
Connected Persons**

The Administrators of the GlaxoSmithKline Executive Supplemental Savings Plan notified the Company and the under-mentioned person

on

11

July  
2008  
of changes  
to his  
interests in Ordinary s  
hare ADRs a  
rising from an increase in his  
interests under the Annual Investment Plan feature following the re-investment of the dividend paid to shareholders on

10 July

2008

at a price of \$

48.40

per

ADR

:-

Dr D Pulman 24.40

This notification relates to a transaction notified in accordance with

Disclosure  
and Transparency

R

ule 3.1.4R(1)(a)

.

S M Bicknell  
Company Secretary

11

July

2008

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: July 11, 2008

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc